logo
Veracyte price target lowered to $28 from $29 at Morgan Stanley

Veracyte price target lowered to $28 from $29 at Morgan Stanley

Morgan Stanley analyst Tejas Savant lowered the firm's price target on Veracyte (VCYT) to $28 from $29 and keeps an Underweight rating on the shares. The company reported a solid Q2 beat on continued Decipher/Afirma momentum leading to a 2025 guidance raise, the analyst tells investors in a research note. The firm added that Veracyte's pipeline is promising an represents substantial opportunity, though meaningful upside remains a 2027+ dynamic.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CoreWeave (CRWV) Insiders Sell over $1B Worth of Shares as IPO Lock-Up Period Ends
CoreWeave (CRWV) Insiders Sell over $1B Worth of Shares as IPO Lock-Up Period Ends

Business Insider

timean hour ago

  • Business Insider

CoreWeave (CRWV) Insiders Sell over $1B Worth of Shares as IPO Lock-Up Period Ends

CoreWeave (CRWV) insiders began selling shares today after the AI data center company's IPO lock-up period expired. As a result, this triggered more than $1 billion in block trades that were organized by Morgan Stanley (MS), JPMorgan Chase (JPM), and Goldman Sachs (GS). Among those selling was board director Jack Cogen, who sold nearly $300 million worth of stock. Interestingly, even though CoreWeave's stock had plunged by 35% in the previous two days due to disappointing second-quarter results, shares stabilized around the $100 level to close slightly up on the day. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The spike in trading activity happened because about 84% of CoreWeave's Class A shares became available for the first time since its IPO in March. According to the Financial Times, which cited sources close to the matter, banks scrambled on Thursday evening to arrange block trades as large as six to eight million shares. For context, block trades like these allow large investors to sell shares quietly, often at a discount, without overwhelming the market. Nevertheless, while CoreWeave has benefited from the AI infrastructure boom, concerns about its financial health are growing. Indeed, the company reported rising losses and surging operating expenses, which hit $1.2 billion in Q2 – almost four times higher than a year ago. On top of that, CoreWeave is facing investor pushback over its proposed $9 billion acquisition of Core Scientific (CORZ), as some shareholders of the target company have threatened to vote against it unless better terms are offered. It also doesn't help that, as of Thursday, 46% of CoreWeave's tradable shares were being shorted, thereby indicating that many investors are betting that the stock will continue to fall. Is CRWV a Good Stock to Buy? Turning to Wall Street, analysts have a Hold consensus rating on CRWV stock based on six Buys, 16 Holds, and two Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average CRWV price target of $115.29 per share implies 15.3% upside potential.

Meta intends to divide Superintelligence Labs into four groups, Information says
Meta intends to divide Superintelligence Labs into four groups, Information says

Business Insider

time3 hours ago

  • Business Insider

Meta intends to divide Superintelligence Labs into four groups, Information says

Meta Platforms (META) will undergo its fourth restructuring of its AI efforts in six months, The Information's Kalley Huang reports, citing three people familiar with the matter. The Facebook parent's new AI organization, Meta Superintelligence Labs, is anticipated to be divided into four groups as part of the restructuring, the author notes. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store